- Home
- SWTX
as 07-26-2024 4:00pm EST
SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | STAMFORD |
| Market Cap: | 3.1B | IPO Year: | 2019 |
| Target Price: | $66.60 | AVG Volume (30 days): | 785.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.15 | EPS Growth: | N/A |
| 52 Week Low/High: | $18.00 - $53.92 | Next Earning Date: | 08-07-2024 |
| Revenue: | $26,453,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 2459.39% | Revenue Growth (next year): | 132.96% |
Stock Insider Trading Activity of SpringWorks Therapeutics Inc. (SWTX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Islam Saqib | SWTX | Chief Executive Officer | Jun 3 '24 | Sell | $42.09 | 400 | $16,837.00 | 1,112,368 | SEC Form 4 |
| Islam Saqib | SWTX | Chief Executive Officer | Jun 3 '24 | Sell | $41.40 | 6,600 | $273,246.60 | 1,112,768 | SEC Form 4 |
| Islam Saqib | SWTX | Chief Executive Officer | Jun 3 '24 | Sell | $40.57 | 8,760 | $355,363.42 | 1,119,368 | SEC Form 4 |
| Islam Saqib | SWTX | Chief Executive Officer | Jun 3 '24 | Sell | $39.40 | 33,240 | $1,309,665.97 | 1,128,128 | SEC Form 4 |
| Edris Badreddin | SWTX | Chief Operating Officer | Jun 3 '24 | Sell | $42.04 | 385 | $16,184.09 | 249,600 | SEC Form 4 |
| Edris Badreddin | SWTX | Chief Operating Officer | Jun 3 '24 | Sell | $41.38 | 3,651 | $151,066.33 | 249,985 | SEC Form 4 |
| Edris Badreddin | SWTX | Chief Operating Officer | Jun 3 '24 | Sell | $40.62 | 4,192 | $170,287.00 | 253,636 | SEC Form 4 |
| Edris Badreddin | SWTX | Chief Operating Officer | Jun 3 '24 | Sell | $39.40 | 11,772 | $463,834.46 | 257,828 | SEC Form 4 |
| Hambleton Julie | SWTX | Director | Jun 3 '24 | Sell | $42.09 | 20 | $841.81 | 4,095 | SEC Form 4 |
| Hambleton Julie | SWTX | Director | Jun 3 '24 | Sell | $41.49 | 931 | $38,629.42 | 4,115 | SEC Form 4 |
| Hambleton Julie | SWTX | Director | Jun 3 '24 | Sell | $40.57 | 751 | $30,465.44 | 5,046 | SEC Form 4 |
| Hambleton Julie | SWTX | Director | Jun 3 '24 | Sell | $39.41 | 2,946 | $116,111.29 | 5,797 | SEC Form 4 |
| Pichl Daniel | SWTX | Chief People Officer | Feb 16 '24 | Sell | $50.10 | 15,000 | $751,549.50 | 45,212 | SEC Form 4 |
| Ashar Bhavesh | SWTX | Chief Commercial Officer | Feb 2 '24 | Sell | $43.75 | 1,089 | $47,639.94 | 65,121 | SEC Form 4 |
| Ashar Bhavesh | SWTX | Chief Commercial Officer | Feb 2 '24 | Sell | $44.31 | 1,667 | $73,867.94 | 63,454 | SEC Form 4 |
| Ashar Bhavesh | SWTX | Chief Commercial Officer | Feb 2 '24 | Sell | $46.00 | 378 | $17,387.21 | 63,076 | SEC Form 4 |
| Ashar Bhavesh | SWTX | Chief Commercial Officer | Feb 2 '24 | Sell | $46.37 | 88 | $4,080.85 | 62,988 | SEC Form 4 |
| Ashar Bhavesh | SWTX | Chief Commercial Officer | Feb 2 '24 | Sell | $49.32 | 4,834 | $238,434.63 | 58,154 | SEC Form 4 |
| Pichl Daniel | SWTX | Chief People Officer | Feb 2 '24 | Sell | $43.81 | 9,266 | $405,941.61 | 62,127 | SEC Form 4 |
| Pichl Daniel | SWTX | Chief People Officer | Feb 2 '24 | Sell | $44.31 | 14,175 | $628,156.62 | 47,952 | SEC Form 4 |
| Pichl Daniel | SWTX | Chief People Officer | Feb 2 '24 | Sell | $45.95 | 1,997 | $91,756.36 | 45,955 | SEC Form 4 |
| Pichl Daniel | SWTX | Chief People Officer | Feb 2 '24 | Sell | $46.44 | 743 | $34,507.07 | 45,212 | SEC Form 4 |
Latest SpringWorks Therapeutics Inc. News
SWTX Breaking Stock News: Dive into SWTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
GlobeNewswire
a month ago
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
GuruFocus.com
2 months ago
Insider Sale: Director Julie Hambleton Sells Shares of SpringWorks Therapeutics Inc (SWTX)
GuruFocus.com
2 months ago
Insider Sale: COO Badreddin Edris Sells 20,000 Shares of SpringWorks Therapeutics Inc (SWTX)
GuruFocus.com
2 months ago
Insider Sale: CEO Saqib Islam Sells 49,000 Shares of SpringWorks Therapeutics Inc (SWTX)
GlobeNewswire
2 months ago
SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewswire
2 months ago
SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
3 months ago
SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
Compare SWTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SWTX SpringWorks Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.